Published in Food and Drug Law Weekly, October 27th, 2006
This session provided an open forum in which to discuss the complex scientific issues surrounding the risk/benefit profile of Trasylol (aprotinin injection) in detail.
At the end of the session, the committee overwhelmingly affirmed (18 yes votes and one abstention) that the totality of clinical data presented in today's meeting supports acceptable safety and efficacy for Trasylol among coronary artery bypass graft (CABG) surgery patients.
Additionally, as noted in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.